-
News | 2020.11.30
Report on the 52nd International Network Council of Directors meeting – lessons to be drawn from the COVID-19 pandemic in the International Network
The 52nd meeting of the Institut Pasteur International Network Council of Directors was held from November, 17 to 20. Because of the extraordinary events this year, the latest meeting took place entirely on a remote basis.The physical absence of the participants did not hinder the presentations, discussions and good humor of the meeting, which was greatly facilitated by simultaneous...
-
Document de presse | 2021.09.21
Covid-19: study on the effectiveness of immune memory after mRNA vaccination to recognize variants of SARS-CoV-2
The teams from Henri-Mondor AP-HP hospital and Paris-Est Créteil University, Inserm, CNRS, University of Paris, within the Necker-Enfants Malades Institute, and the Institut Pasteur analyzed the capacity of the immune memory generated after mRNA vaccination to recognize and neutralize SARS-CoV-2 variants.This work, coordinated by Prof. Matthieu Mahévas, Dr Claude-Agnès Reynaud, Prof. Jean-Claude...
-
News | 2021.02.01
COVID-19: New diagnostic tool for use outside the lab, offering the same efficacy as a PCR test
PCR tests are currently the gold standard for detecting SARS-CoV-2. These tests are reliable, but their complexity makes them difficult to use for point-of-care testing (POCT), in other words testing outside the laboratory. Scientists from the Institut Pasteur and ESPCI Paris-PSL have developed COVIDISC, a new portable device for this purpose. Since 2014, Institut Pasteur scientists have...
-
Document de presse | 2021.01.25
COVID-19: progress update on the Institut Pasteur's scientific response and vaccine candidate research programs
Since early 2020, the Institut Pasteur has been engaged in research in several of its areas of scientific expertise, including virology, diagnostics, pathophysiology, epidemiology, modeling, therapeutic research and vaccine research. A number of research programs to find a vaccine for SARS-CoV-2, the virus responsible for the COVID-19 epidemic, are under way. In light of the intermediate results...
-
News | 2020.11.04
COVID-19: Senlis Criminal Court convicts the author of a fake news video for defamation
On November 2, 2020, Senlis Criminal Court convicted the author of a misleading video claiming that the Institut Pasteur invented COVID-19, posted online on March 17, 2020, of public defamation towards the Institut Pasteur. The author's words, which were untrue and unfounded and were based on a misinterpretation of a patent submitted in 2004, led to a wave of strong reactions against the Institut...
-
Document de presse | 2021.01.19
COVID-19: a lentiviral vaccine candidate for intranasal administration provides sterilizing protection in animal models
Scientists from the Institut Pasteur-TheraVectys Joint Laboratory recently published in Cell Host & Microbe1 the results of tests, in two preclinical models, of a COVID-19 vaccine candidate using a lentiviral vector administered by nasal route. Their study demonstrates that the vaccine candidate induces antibody response with strong neutralizing activity against SARS-CoV-2, as well as...
-
News | 2020.09.23
Meningococcus and COVID-19: fewer cases of meningitis but higher incidence of pneumonia observed during the lockdown in early 2020
Although the lockdown introduced in spring 2020 undoubtedly slowed down the circulation of the coronavirus, it also had an impact on other communicable diseases. Scientists from the Institut Pasteur investigated the repercussions of the lockdown period on meningococcal diseases by comparing the number of cases between January 1 and May 15, 2019 with the number of cases over the same period in...
-
Document de presse | 2021.05.28
COVID-19: analysis of the sensitivity of the Delta variant to monoclonal antibodies and sera from convalescent and vaccinated individuals
The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world. It is now dominant in many countries and regions (India, the UK, Portugal, Russia, etc.) and is predicted to be the most prevalent variant in Europe within weeks or months. Epidemiological studies have shown that the Delta variant is more transmissible than other variants....
-
Article | 2020.06.16
Development of simple Covid-19 serological tools and targeted serosurvey of at-risk individuals
Aim: to develop simple serological tools that can be used to establish three tests: an enzyme-linked immunosorbent assay (ELISA), an immunofluorescence assay (IFA) and multiplex microsphere-based immunoassays (MIAs – capable of detecting several targets). This research will pave the way for the serological investigation of at-risk individuals such as those working at animal markets, farmers...
-
Article | 2020.06.16
Red Cross health workers and volunteers and continuity of care with COVID-19: an operational approach using mixed methods
Aim: to study social and cultural challenges encountered by French Red Cross health workers and volunteers (who work with healthcare facilities/hospitals, nursing homes, etc. as well as those working in the field to assist migrants, homeless people, and frail and elderly people) and monitor communication in mainstream and social media to adapt the response to the pandemic in each region. By...
